Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Rating of “Buy” from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $81.29.

Several analysts have recently commented on the stock. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. William Blair assumed coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC grew its holdings in shares of Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock valued at $112,816,000 after buying an additional 203,010 shares during the last quarter. Deep Track Capital LP boosted its stake in Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP increased its holdings in Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after purchasing an additional 575,000 shares in the last quarter. Capital International Investors raised its stake in shares of Structure Therapeutics by 6.8% in the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company’s stock worth $43,909,000 after purchasing an additional 103,059 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company’s stock worth $38,512,000 after purchasing an additional 322,601 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Up 17.4 %

Shares of NASDAQ GPCR opened at $21.76 on Friday. The company has a market capitalization of $1.25 billion, a PE ratio of -29.41 and a beta of -1.35. The firm has a fifty day simple moving average of $20.23 and a 200 day simple moving average of $28.51. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.